← Back to Screener
Shattuck Labs, Inc. Common Stock (STTK)
Price$4.75
Value ScoreF
Growth ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)122.82%
Price vs S&P 500 (4W)-30.48%
VGM Score34.05
Market Capitalization$373.43M
All Metrics
Book Value / Share (Quarterly)$1.27
P/TBV (Annual)0.58x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)15.44%
Cash Flow / Share (Quarterly)$-0.55
Price vs S&P 500 (YTD)22.04%
Net Profit Margin (TTM)-1005.60%
EPS (TTM)$-0.64
10-Day Avg Trading Volume0.60M
EPS Excl Extra (TTM)$-0.64
Revenue Growth (5Y)-36.82%
EPS (Annual)$-0.70
ROI (Annual)-59.24%
Net Profit Margin (5Y Avg)-5460.38%
Cash / Share (Quarterly)$1.20
Revenue Growth QoQ (YoY)-66.63%
ROA (Last FY)-53.62%
Revenue Growth TTM (YoY)-78.29%
EBITD / Share (TTM)$-0.58
ROE (5Y Avg)-57.74%
Operating Margin (TTM)-1071.60%
Cash Flow / Share (Annual)$-0.63
P/B Ratio3.90x
P/B Ratio (Quarterly)5.06x
Net Income / Employee (Annual)$-1,220,200
EV / Revenue (TTM)283.01x
Net Interest Coverage (TTM)-3.43x
ROA (TTM)-55.75%
EPS Incl Extra (Annual)$-0.70
Current Ratio (Annual)11.70x
Quick Ratio (Quarterly)21.28x
3-Month Avg Trading Volume0.61M
52-Week Price Return366.03%
Revenue / Employee (TTM)$25,000
Tangible BV / Share (Quarterly)$2.65
P/S Ratio (Annual)373.43x
Asset Turnover (Annual)0.01x
52-Week High$8.33
Operating Margin (5Y Avg)-5631.28%
EPS Excl Extra (Annual)$-0.70
CapEx CAGR (5Y)-37.25%
26-Week Price Return136.41%
Quick Ratio (Annual)11.07x
13-Week Price Return21.75%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.06x
Enterprise Value$283.01M
Revenue / Share Growth (5Y)-42.92%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-29.38%
Revenue / Employee (Annual)$25,000
Pretax Margin (Annual)-4880.90%
Cash / Share (Annual)$1.23
3-Month Return Std Dev75.90%
Net Income / Employee (TTM)$-1,246,800
ROE (Last FY)-59.24%
EPS Basic Excl Extra (Annual)$-0.70
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.64
ROI (TTM)-60.73%
P/S Ratio (TTM)373.43x
Pretax Margin (5Y Avg)-5460.38%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$4.16
Price vs S&P 500 (52W)337.88%
Year-to-Date Return33.42%
5-Day Price Return-19.64%
EPS Normalized (Annual)$-0.70
ROA (5Y Avg)-51.17%
Net Profit Margin (Annual)-4880.90%
Month-to-Date Return-18.15%
Cash Flow / Share (TTM)$-2.14
EBITD / Share (Annual)$-0.69
Operating Margin (Annual)-5150.80%
ROI (5Y Avg)-57.74%
EPS Basic Excl Extra (TTM)$-0.64
P/TBV (Quarterly)0.90x
P/B Ratio (Annual)2.80x
Pretax Margin (TTM)-1005.60%
Book Value / Share (Annual)$1.30
Price vs S&P 500 (13W)11.09%
Beta1.02x
Revenue / Share (TTM)$0.01
ROE (TTM)-60.73%
52-Week Low$0.71
vGradeF
gGradeF
mGradeB
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.13est. -0.14
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.08
4.07
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
STTKShattuck Labs, Inc. Common Stock | F | F | B | $4.75 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Shattuck Labs develops novel antibody therapeutics for inflammatory and immune-mediated diseases. Its lead program, SL-325, is a potentially first-in-class DR3 antagonist antibody for inflammatory bowel disease, with a pipeline including SL-425 (an extended half-life variant) and bispecific antibodies based on its protein engineering platform.